Secondary Central Nervous System Lymphoma
12 clinical trials · Condition
◉ Watch Secondary Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma (NCT05351593) | James Rubenstein | 2022-06-08 |
| R-MTX-zanbrutinib in Secondary CNS Lymphoma (NCT05398224) | Peking University | 2021-02-26 |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) (NCT04457869) | Shandong New Time Pharmaceutical Co., LTD | 2020-11-01 |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies (NCT05011045) | M.D. Anderson Cancer Center | 2020-01-09 |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (NCT03964090) | National Cancer Institute (NCI) | 2019-06-27 |
| A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL (NCT04438044) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-06-18 |
Track Secondary Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.